Sarepta Therapeutics CEO Ingram to retire by year end

Core Viewpoint - Sarepta Therapeutics CEO Douglas Ingram will retire by the end of 2026 or upon the appointment of a successor, following a challenging year for the company marked by significant setbacks related to its gene therapy product, Elevidys [1]. Company Developments - The company has initiated a search for a new CEO after Ingram's announcement of his retirement [1]. - Sarepta faced a tumultuous 2025, with Elevidys linked to the deaths of two patients, leading to a request from the U.S. Food and Drug Administration (FDA) to voluntarily halt shipments of the therapy [1]. - The FDA is currently investigating the deaths associated with Elevidys, which has resulted in the therapy carrying the most serious safety warning and stringent monitoring requirements post-treatment [1]. Financial Impact - Sarepta announced 500 job cuts and halted the development of several gene therapies for limb-girdle muscular dystrophy in response to the challenges faced [1]. - The company's shares fell by 82% last year, reflecting the negative market reaction to the issues surrounding Elevidys [1]. - Following the announcement of Ingram's retirement, the stock was down approximately 4% in after-market trading [1].